MARKET

ATXS

ATXS

Astria Therapeutics Inc
NASDAQ
12.93
-0.19
-1.45%
After Hours: 12.93 0 0.00% 17:01 12/05 EST
OPEN
13.14
PREV CLOSE
13.12
HIGH
13.18
LOW
12.84
VOLUME
531.52K
TURNOVER
--
52 WEEK HIGH
13.29
52 WEEK LOW
3.555
MARKET CAP
738.11M
P/E (TTM)
-6.0474
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ATXS last week (1124-1128)?
Weekly Report · 6d ago
Astria Therapeutics: Updating Target Price, Biocryst Deal Expected To Go Through, Hold
Seeking Alpha · 11/30 06:29
Weekly Report: what happened at ATXS last week (1117-1121)?
Weekly Report · 11/24 10:26
Weekly Report: what happened at ATXS last week (1110-1114)?
Weekly Report · 11/17 10:26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Codexis (CDXS), Milestone Pharmaceuticals (MIST) and Astria Therapeutics (ATXS)
TipRanks · 11/13 14:40
Astria Therapeutics Reports Q3 2025 Results and BioCryst Acquisition
TipRanks · 11/13 04:24
Astria Therapeutics: Hold Rating Amid Acquisition and Financial Stability with Future Growth Prospects
TipRanks · 11/12 21:35
Astria Therapeutics Cut to Neutral From Overweight by Cantor Fitzgerald
Dow Jones · 11/12 19:17
More
About ATXS
Astria Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for allergic and immunological diseases. Its lead product candidate is Navenibart, a potential monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, autosomal dominant genetic disorder. Its second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis (AD), an immune disorder associated with loss of skin barrier function and itching. It owns five patent families directed to navenibart. The first patent family is directed to the composition of matter of navenibart and its use in treating various plasma kallikrein associated disorders, including HAE. In the second patent family, it is directed to methods of treating various plasma-kallikrein-associated disorders, including HAE.

Webull offers Astria Therapeutics Inc stock information, including NASDAQ: ATXS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATXS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATXS stock methods without spending real money on the virtual paper trading platform.